echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Drugs Articles > Drug companies to reduce wages and lay off staff frequently, pharmaceutical representatives need to return to academic promotion.

    Drug companies to reduce wages and lay off staff frequently, pharmaceutical representatives need to return to academic promotion.

    • Last Update: 2020-07-30
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    Pharmaceutical S.C. Market Analysis: Takeda Pharmaceuticals is considering cutting the number of sales staff in Japan as part of a restructuring effort following its acquisition of British drugmaker Shire, according to people familiar with the matter.said Takeda's job cuts would focus on sales positions.wants to reduce the number of medical representatives who sell products to doctors and hospitals and rely more on contract sales to increase flexibility.the news, Takeda Pharmaceuticals said it had not made any decision on the job cuts and said it would disclose more information after consultation with the union.in fact, from the current pharmaceutical industry's background, due to market competition, rising costs and the impact of this year's special period, the global pharmaceutical companies are facing greater revenue pressure, need to reduce costs.this year, a number of multinational pharmaceutical companies have been announced to cut wages and lay off the news, of which pharmaceutical representatives have become the layoff list of "regular slots.", for example, Uk-based pharmaceutical company Orchard Therapeutics, for example, said it had cut about a quarter of its workforce to save cash flow, abandoned construction at its Plant in California and shifted its clinical focus to high-value, high-demand products.separately, Mercado announced the divestiture of women's health products, mature products and biosimilars to form a new company; Sanofi announced the merger of six API production sites in Europe to create an independent API company, as well as plans to spin off the consumer health business; GSK plans to spin off some of its antibiotic business; and biotech company Sage announced plans to lay off 340 employees, or about 53 percent of the company's total.behind these actions, have brought some medical representatives, research and development personnel post changes.is not only a multinational pharmaceutical enterprises, domestic enterprises related to the action is also frequent.for example, at the beginning of this year, Watson Pharmaceuticals, Enhua Pharmaceuticals, Hengrui Pharmaceuticals and other well-known pharmaceutical companies also made adjustments to the sales sector, and even explicitly reduced the investment in the sales sector.at the same time, the compliance needs of pharmaceutical companies are becoming increasingly important.in the volume of procurement, tax and tax verification, to drug recruitment credit evaluation system, as well as the annual emphasis on the "correction of the pharmaceutical purchase and sale of the field and medical services in the wrong wind" related notice implementation, the pharmaceutical purchase and sale of commercial bribery will be a heavy blow, the space for gold sales is being greatly compressed.early June, the State Medical Insurance Administration on the establishment of "the establishment of pharmaceutical prices and credit evaluation system guidance" for the second time to solicit opinions from all walks of life, proposed the establishment of pharmaceutical enterprise prices and marketing behavior commitment to keep faith and other six systems, clear pharmaceutical companies to be agents of commercial bribery joint and several responsibilities, including the failure to accept the credibility will lose recruitment qualifications.July 24, the National Health and Care Commission issued "on the issuance of the 2020 medical industry style construction special action plan notice", clear from July this year to the end of the year, will focus on the treatment of medical personnel to collect kickbacks, pharmaceutical companies illegal marketing behavior.mentioned to investigate and punish in medical institutions outpatient, inpatient, pharmacy and other areas of pharmaceutical products production, business enterprises or distribution personnel illegally to medical personnel to promote the sale of drugs, medical equipment, business negotiations. industry generally believes that this also means that medical representatives will be more limited in access to hospitals to visit doctors. trends, non-compliant pharmaceutical purchases and sales represent significant risks for pharmaceutical representatives as well as pharmaceutical companies. the future, medical representatives urgently need to return to academic promotion, in order not to be shuffled out. .
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.